Literature DB >> 31009120

N-Methyl-d-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats.

Jan Hoffmann1,2, Robin James Storer1,3, Jeong-Wook Park4, Peter J Goadsby1,2.   

Abstract

Experimental and clinical studies suggest that the low-affinity N-methyl-d-aspartate (NMDA) receptor open-channel blockers Mg2+ and memantine are effective in reducing trigeminal nociceptive activation. The aim of this study was to investigate the apparent effectiveness of these channel blockers using a model of trigeminal activation in vivo. Rats were anaesthetized before electrically stimulating the dura mater adjacent the middle meningeal artery. Neurons responding to stimulation were recorded extracellularly using electrophysiological methods. l-Glutamate or NMDA, and Mg2+ , memantine, or sodium controls were applied locally using microiontophoresis. Microiontophoretic application of Mg2+ or memantine into the trigeminocervical complex inhibited mechanically and electrically stimulated craniovascular afferents,  and l-glutamate or NMDA-evoked neuronal activity at the second-order trigeminal synapse of craniovascular afferents. By contrast, intravenous administration of MgSO4 (100 mg/kg) or memantine (10 mg/kg) did not significantly affect electrically stimulated afferent-evoked activity within the trigeminocervical complex. The Mg2+ and memantine concentrations achieved after systemic administration may not effectively inhibit activation of the trigeminocervical complex, perhaps providing an explanation for the relatively poor efficacy of these NMDA receptor open-channel blockers for headache treatment in clinical studies. Nevertheless, the present results suggest blocking of NMDA-receptor open channels inhibits nociceptive activation of the trigeminocervical complex. Further exploration of such channel blockers as a therapeutic strategy for primary head pain is warranted.
© 2019 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  glutamate; headache; microiontophoresis; migraine; naratriptan

Mesh:

Substances:

Year:  2019        PMID: 31009120      PMCID: PMC7611086          DOI: 10.1111/ejn.14423

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.698


  52 in total

1.  Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients.

Authors:  P Sarchielli; G Coata; C Firenze; P Morucci; G Abbritti; V Gallai
Journal:  Cephalalgia       Date:  1992-02       Impact factor: 6.292

Review 2.  The role of ketamine in pain management.

Authors:  E Visser; S A Schug
Journal:  Biomed Pharmacother       Date:  2006-07-05       Impact factor: 6.529

Review 3.  Use of oral ketamine in chronic pain management: a review.

Authors:  Maren I Blonk; Brigitte G Koder; Patricia M L A van den Bemt; Frank J P M Huygen
Journal:  Eur J Pain       Date:  2009-10-29       Impact factor: 3.931

Review 4.  Ketamine in chronic pain management: an evidence-based review.

Authors:  Graham Hocking; Michael J Cousins
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

Review 5.  Therapeutic potential of novel glutamate receptor antagonists in migraine.

Authors:  Anna P Andreou; Peter J Goadsby
Journal:  Expert Opin Investig Drugs       Date:  2009-06       Impact factor: 6.206

6.  Low brain magnesium in migraine.

Authors:  N M Ramadan; H Halvorson; A Vande-Linde; S R Levine; J A Helpern; K M Welch
Journal:  Headache       Date:  1989-07       Impact factor: 5.887

7.  Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study.

Authors:  M E Bigal; C A Bordini; S J Tepper; J G Speciali
Journal:  Cephalalgia       Date:  2002-06       Impact factor: 6.292

8.  Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study.

Authors:  Rezvan Noruzzadeh; Amirhossein Modabbernia; Vajiheh Aghamollaii; Majid Ghaffarpour; Mohammad Hossein Harirchian; Sarvenaz Salahi; Nikta Nikbakht; Nahid Noruzi; Abbas Tafakhori
Journal:  Headache       Date:  2015-12-06       Impact factor: 5.887

9.  Memantine selectively depresses NMDA receptor-mediated responses of ratspinal neurones in vivo.

Authors:  J F Herrero; P M Headley; C G Parsons
Journal:  Neurosci Lett       Date:  1994-01-03       Impact factor: 3.046

10.  From Static to Interactive: Transforming Data Visualization to Improve Transparency.

Authors:  Tracey L Weissgerber; Vesna D Garovic; Marko Savic; Stacey J Winham; Natasa M Milic
Journal:  PLoS Biol       Date:  2016-06-22       Impact factor: 8.029

View more
  1 in total

Review 1.  Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?

Authors:  Tarique Benbow; Brian E Cairns
Journal:  Cephalalgia       Date:  2021-06-20       Impact factor: 6.292

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.